EXEL icon

Exelixis

36.85 USD
+0.68
1.88%
Updated May 12, 11:18 AM EDT
1 day
1.88%
5 days
-6.42%
1 month
3.11%
3 months
12.35%
6 months
2.79%
Year to date
8.57%
1 year
73.25%
5 years
37.19%
10 years
901.36%
 

About: Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Employees: 1,147

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 10 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

166% more first-time investments, than exits

New positions opened: 117 | Existing positions closed: 44

31% more capital invested

Capital invested by funds: $6.37B [Q3] → $8.33B (+$1.96B) [Q4]

29% more funds holding in top 10

Funds holding in top 10: 7 [Q3] → 9 (+2) [Q4]

18% more call options, than puts

Call options by funds: $58.6M | Put options by funds: $49.7M

15% more funds holding

Funds holding: 447 [Q3] → 512 (+65) [Q4]

1.47% more ownership

Funds ownership: 86.06% [Q3] → 87.53% (+1.47%) [Q4]

4% more repeat investments, than reductions

Existing positions increased: 172 | Existing positions reduced: 165

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$29
21%
downside
Avg. target
$38
2%
upside
High target
$45
22%
upside

10 analyst ratings

positive
60%
neutral
40%
negative
0%
JMP Securities
Silvan Tuerkcan
20% 1-year accuracy
10 / 51 met price target
11%upside
$41
Market Outperform
Reiterated
17 Apr 2025
HC Wainwright & Co.
Robert Burns
17% 1-year accuracy
29 / 167 met price target
9%upside
$40
Buy
Reiterated
27 Mar 2025
RBC Capital
Gregory Renza
19% 1-year accuracy
15 / 78 met price target
9%upside
$40
Outperform
Maintained
13 Mar 2025
Wells Fargo
Derek Archila
48% 1-year accuracy
14 / 29 met price target
2%downside
$36
Equal-Weight
Downgraded
24 Feb 2025
Barclays
Peter Lawson
4% 1-year accuracy
1 / 24 met price target
21%downside
$29
Equal-Weight
Maintained
13 Feb 2025

Financial journalist opinion

Based on 10 articles about EXEL published over the past 30 days

Positive
Zacks Investment Research
4 days ago
Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Exelixis (EXEL), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Ahead of Exelixis (EXEL) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Neutral
Business Wire
4 days ago
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities 2025 Health Care Conference: Exelixis is scheduled to present at 1:40 p.m. ET / 10:40 a.m. PT on Wednesday, May 14 in Las Vegas. RBC Capital Markets 2025 Global Healthcare Conference: Exelixis is scheduled to present at 10:30 a.m. ET / 7:30 a.m. PT on Tuesday, May 20 in New York City. To access th.
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
Positive
Zacks Investment Research
1 week ago
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Neutral
Business Wire
1 week ago
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2025 financial results will be released on Tuesday, May 13, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon regis.
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
Neutral
GlobeNewsWire
1 week ago
EXEL Industries: Second quarter 2024–2025 sales down 3.8%
Q2 2024–2025 revenue: -3.8% Businesses proved to be resilient in an uncertain economic context Q2 sales (January 2025–March 2025))   2023–2024 2024–2025 Change (reported) Change (LFL*) Reported Reported €m % €m % AGRICULTURAL SPRAYING 157.4 132.7 -24.7 -15.7% -25.2 -16.0% SUGAR BEET HARVESTING   17.1 25.3 +8.1 +47.6% +9.4 +54.7% LEISURE   47.4 47.3 -0.0 -0.1% -0.4 -0.8% INDUSTRY   70.7 76.0 +5.3 +7.5% +3.7 +5.2% EXEL Industries Group 292.6 281.4 -11.3 -3.8% -12.6 -4.3% Like-for-like (LFL) = at constant consolidation scope and foreign exchange rates 6-month sales (October 2024–March 2025))   2023–2024 2024–2025 Change (reported) Change (LFL*) Reported Reported €m % €m % AGRICULTURAL SPRAYING 248.3 194.9 -53.4 -21.5% -53.7 -21.6% SUGAR BEET HARVESTING   44.2 44.4 +0.2 +0.4% +1.1 +2.6% LEISURE   58.5 60.2 +1.8 +3.0% -0.5 -0.8% INDUSTRY   141.7 143.9 +2.2 +1.5% +1.8 +1.3% EXEL Industries Group 492.7 443.4 -49.4 -10.0% -51.3 -10.4% Like-for-like (LFL) = at constant consolidation scope and foreign exchange rates Q2 revenue 2024-2025 The EXEL Industries Group generated revenue of €281.4 million in the second quarter of the 2024-2025 fiscal year, down -3.8% on the previous year, mainly due to lower volumes in Agricultural Spraying, with other activities either stable or growing. At constant scope and foreign exchange rates, revenue was down -4.3%.
EXEL Industries: Second quarter 2024–2025 sales down 3.8%
Positive
Investors Business Daily
2 weeks ago
MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points
Stocks near buy points include Charles Schwab, German software leader SAP and MercadoLibre, the so-called Amazon of Latin America,
MercadoLibre, The Amazon Of Latin America, Leads Five Stocks Near Buy Points
Neutral
Zacks Investment Research
2 weeks ago
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
Investors will likely focus on the demand for Cabometyx and pipeline updates when EXEL reports Q1 results.
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
Positive
Zacks Investment Research
2 weeks ago
Here's Why Exelixis (EXEL) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Exelixis (EXEL) is a Strong Value Stock
Positive
Zacks Investment Research
2 weeks ago
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Positive
Zacks Investment Research
3 weeks ago
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Charts implemented using Lightweight Charts™